--- title: "Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Short Interest Update" type: "News" locale: "en" url: "https://longbridge.com/en/news/280976660.md" description: "Adlai Nortye Ltd. (NASDAQ:ANL) experienced a significant increase in short interest in March, rising 27.1% to 1,065,214 shares. The short-interest ratio is currently 5.5 days, with 2.9% of shares sold short. Analysts have mixed ratings, with Weiss Ratings maintaining a 'sell' and HC Wainwright upgrading to 'buy' with a $16 target. The stock opened at $6.46, with a one-year range of $0.88 to $12.09. Adlai Nortye specializes in fine chemicals, particularly amino acids and derivatives, serving various markets including animal feed and pharmaceuticals." datetime: "2026-03-30T07:59:52.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/280976660.md) - [en](https://longbridge.com/en/news/280976660.md) - [zh-HK](https://longbridge.com/zh-HK/news/280976660.md) --- # Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Short Interest Update Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL - Get Free Report) saw a large increase in short interest in the month of March. As of March 13th, there was short interest totaling 1,065,214 shares, an increase of 27.1% from the February 26th total of 837,841 shares. Based on an average daily volume of 194,283 shares, the days-to-cover ratio is presently 5.5 days. Currently, 2.9% of the shares of the company are sold short. ## Analyst Upgrades and Downgrades A number of brokerages have recently commented on ANL. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Adlai Nortye in a research report on Wednesday, January 21st. HC Wainwright upgraded Adlai Nortye from a "neutral" rating to a "buy" rating and set a $16.00 price target on the stock in a research note on Friday, February 13th. Wall Street Zen raised Adlai Nortye to a "hold" rating in a report on Saturday, March 7th. Finally, Leerink Partners initiated coverage on Adlai Nortye in a research report on Friday, March 20th. They issued an "outperform" rating and a $23.00 price objective for the company. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Adlai Nortye presently has a consensus rating of "Hold" and an average target price of $19.50. **Check Out Our Latest Research Report on ANL** ## Adlai Nortye Stock Performance Adlai Nortye stock opened at $6.46 on Monday. The business has a 50 day simple moving average of $7.77 and a 200 day simple moving average of $3.74. Adlai Nortye has a one year low of $0.88 and a one year high of $12.09. ## About Adlai Nortye (Get Free Report) Adlai Nortye Inc NASDAQ: ANL is a specialty chemical manufacturer headquartered in China’s Jiangsu Province. The company focuses on the research, development, production and sale of fine chemicals, with a primary emphasis on amino acids and their derivatives. Adlai Nortye’s product portfolio includes betaine compounds, a range of high-purity L-amino acids such as L-methionine, L-threonine and glycine, as well as various chemical intermediates. These offerings serve multiple end markets, including animal feed and nutrition, personal care and cosmetic formulations, pharmaceutical ingredients and industrial chemical processes. The company operates multiple production facilities alongside an in-house research and development center dedicated to process innovation and quality control. ## Read More - Five stocks we like better than Adlai Nortye _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in Adlai Nortye Right Now? Before you consider Adlai Nortye, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adlai Nortye wasn't on the list. While Adlai Nortye currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [ANL.US](https://longbridge.com/en/quote/ANL.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) ## Related News & Research - [Korro Bio To Advance KRRO-111 As Potential Treatment For AATD](https://longbridge.com/en/news/287089978.md) - [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md) - [Eton Pharmaceuticals Adds Another 2026 Launch As It Secures U.S. Rights To IMPAVIDO](https://longbridge.com/en/news/287025596.md) - [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md) - [AbbVie Inc. $ABBV Shares Purchased by RiverFront Investment Group LLC](https://longbridge.com/en/news/286750290.md)